Market Place
Sourcing Support
Xspray Announces Positive FDA Meeting For Dasynoc NDA Resubmission
19 Sep 2024 //
BUSINESSWIRE
Scientific Article in Leading Journal Endorses Xspray Pharma`s HyNap Technology
06 Sep 2024 //
BUSINESSWIRE
Xspray`s XS003 Shows Matching Bioavailability At Lower Dose
09 Jul 2024 //
BUSINESSWIRE
Xspray Ppi Tki Cml Bioavailability: Negative Dasatinib Effects Asco Data
23 May 2024 //
BUSINESSWIRE
After rejection, FDA accepts Xspray`s leukemia med resubmission
12 Feb 2024 //
FIERCE PHARMA
Xspray Pharma’s XS003 Achieves Superior Bioavailability Milestone
21 Nov 2023 //
BUSINESSWIRE
FDA rejects Xspray`s would-be rival to BMS leukemia med Sprycel
12 Jul 2023 //
FIERCE PHARMA
Xspray Partners with EVERSANA for the Commercialization of Dasynoc
23 Feb 2023 //
PR NEWSWIRE
Bristol-Myers Sues XSpray to Block Copies of Blockbuster Sprycel
25 Feb 2022 //
BLOOMBERG LAW
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.